The latest price target for Aptevo Therapeutics (NASDAQ:APVO) was reported by Roth MKM on September 23, 2024. The analyst firm set a price target for $8.00 expecting APVO to rise to within 12 months (a possible 77.40% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Aptevo Therapeutics (NASDAQ:APVO) was provided by Roth MKM, and Aptevo Therapeutics maintained their buy rating.

There is no last upgrade for Aptevo Therapeutics

There is no last downgrade for Aptevo Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptevo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptevo Therapeutics was filed on September 23, 2024 so you should expect the next rating to be made available sometime around September 23, 2025.

While ratings are subjective and will change, the latest Aptevo Therapeutics (APVO) rating was a maintained with a price target of $15.00 to $8.00. The current price Aptevo Therapeutics (APVO) is trading at is $4.51, which is out of the analyst’s predicted range.